Total Payments
$310,148
2024 Payments
$55,598
Companies
45
Transactions
1,074
Medicare Patients
19,827
Medicare Billing
$2.1M
Payment Breakdown by Category
Other$259,497 (83.7%)
Travel$30,241 (9.8%)
Food & Beverage$19,610 (6.3%)
Consulting$500.00 (0.2%)
Education$299.62 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $237,890 | 147 | 76.7% |
| Travel and Lodging | $30,241 | 136 | 9.8% |
| Honoraria | $21,607 | 7 | 7.0% |
| Food and Beverage | $19,610 | 771 | 6.3% |
| Consulting Fee | $500.00 | 1 | 0.2% |
| Education | $299.62 | 12 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $74,471 | 114 | $0 (2024) |
| Gilead Sciences, Inc. | $47,091 | 154 | $0 (2019) |
| Lilly USA, LLC | $45,061 | 64 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $44,067 | 76 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $33,054 | 76 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $32,432 | 123 | $0 (2024) |
| Lexicon Pharmaceuticals, Inc. | $23,771 | 46 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $1,330 | 67 | $0 (2024) |
| Abbott Laboratories | $1,305 | 14 | $0 (2023) |
| Amgen Inc. | $1,262 | 66 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $55,598 | 179 | Lexicon Pharmaceuticals, Inc. ($23,722) |
| 2023 | $106,334 | 219 | Merck Sharp & Dohme LLC ($68,328) |
| 2022 | $37,729 | 147 | Boehringer Ingelheim Pharmaceuticals, Inc. ($19,113) |
| 2021 | $14,445 | 106 | AstraZeneca Pharmaceuticals LP ($12,786) |
| 2020 | $4,835 | 40 | AstraZeneca Pharmaceuticals LP ($4,292) |
| 2019 | $9,250 | 98 | AstraZeneca Pharmaceuticals LP ($7,155) |
| 2018 | $34,648 | 128 | Gilead Sciences, Inc. ($17,592) |
| 2017 | $47,311 | 157 | Gilead Sciences Inc ($29,463) |
All Payment Transactions
1,074 individual payment records from CMS Open Payments — Page 1 of 43
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $24.73 | General |
| Category: Cardiovascular | ||||||
| 12/16/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $23.09 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/13/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $17.08 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/12/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $21.80 | General |
| Category: DIABETES | ||||||
| 12/11/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $20.79 | General |
| Category: Obesity | ||||||
| 12/10/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $22.26 | General |
| Category: Obesity | ||||||
| 12/04/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $21.80 | General |
| Category: DIABETES | ||||||
| 11/25/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $23.99 | General |
| Category: Obesity | ||||||
| 11/21/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $15.17 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/18/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $880.00 | General |
| Category: Diabetes | ||||||
| 11/15/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $27.86 | General |
| Category: Cardiovascular | ||||||
| 11/14/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $24.58 | General |
| Category: Cardiovascular | ||||||
| 11/13/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $880.00 | General |
| Category: Diabetes | ||||||
| 11/13/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $21.24 | General |
| Category: Obesity | ||||||
| 11/13/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: Obesity | ||||||
| 11/07/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/06/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $23.78 | General |
| Category: DIABETES | ||||||
| 11/05/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $25.33 | General |
| Category: Cardio-renal | ||||||
| 10/28/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $24.43 | General |
| Category: Obesity | ||||||
| 10/25/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $22.73 | General |
| Category: Obesity | ||||||
| 10/21/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $21.52 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $16.69 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $21.79 | General |
| Category: DIABETES | ||||||
| 10/09/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $18.10 | General |
| Category: Obesity | ||||||
| 10/08/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $11.69 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 28 | 4,672 | 6,321 | $1.7M | $490,615 |
| 2022 | 32 | 5,266 | 7,076 | $2.1M | $568,018 |
| 2021 | 29 | 5,351 | 7,332 | $1.7M | $608,940 |
| 2020 | 27 | 4,538 | 6,140 | $1.3M | $446,061 |
Total Patients
19,827
Total Services
26,869
Medicare Billing
$2.1M
Procedure Codes
123
All Medicare Procedures & Services
123 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 1,047 | 1,587 | $476,810 | $162,036 | 34.0% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 205 | 205 | $238,620 | $83,977 | 35.2% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 312 | 315 | $327,285 | $52,845 | 16.1% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 182 | 186 | $92,025 | $32,193 | 35.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 1,135 | 1,723 | $86,114 | $20,672 | 24.0% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 116 | 464 | $46,400 | $20,116 | 43.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 115 | 115 | $44,463 | $15,294 | 34.4% |
| 93458 | Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | Facility | 2023 | 64 | 64 | $83,189 | $12,721 | 15.3% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 205 | 205 | $75,030 | $11,401 | 15.2% |
| 92928 | Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | Facility | 2023 | 16 | 18 | $45,771 | $8,555 | 18.7% |
| 93925 | Ultrasound of leg arteries or artery grafts | Office | 2023 | 38 | 38 | $23,628 | $8,517 | 36.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 65 | 82 | $19,836 | $8,346 | 42.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 70 | 71 | $21,603 | $7,723 | 35.8% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2023 | 206 | 206 | $15,644 | $6,272 | 40.1% |
| 92941 | Removal of plaque and blood clot, insertion of stent and/or balloon dilation of single vessel | Facility | 2023 | 12 | 12 | $25,578 | $6,267 | 24.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 65 | 92 | $16,061 | $6,104 | 38.0% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Office | 2023 | 25 | 25 | $14,075 | $4,610 | 32.8% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 21 | 25 | $13,183 | $4,550 | 34.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 47 | 47 | $9,902 | $3,165 | 32.0% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 331 | 411 | $10,021 | $2,892 | 28.9% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 47 | 47 | $19,639 | $2,613 | 13.3% |
| 93978 | Complete ultrasound of aorta, vena cava, groin vessels or bypass grafts | Office | 2023 | 15 | 15 | $6,885 | $2,397 | 34.8% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 87 | 110 | $6,015 | $1,770 | 29.4% |
| 93923 | Complete ultrasound study of arm and leg arteries | Office | 2023 | 17 | 17 | $5,513 | $1,622 | 29.4% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 15 | 17 | $3,627 | $1,274 | 35.1% |
About Dr. Michael Chen, M.D
Dr. Michael Chen, M.D is a Cardiovascular Disease healthcare provider based in Rockville, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1184650954.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Chen, M.D has received a total of $310,148 in payments from pharmaceutical and medical device companies, with $55,598 received in 2024. These payments were reported across 1,074 transactions from 45 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($237,890).
As a Medicare-enrolled provider, Chen has provided services to 19,827 Medicare beneficiaries, totaling 26,869 services with total Medicare billing of $2.1M. Data is available for 4 years (2020–2023), covering 123 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Interventional Cardiology
- Location Rockville, MD
- Active Since 06/24/2006
- Last Updated 08/29/2025
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1184650954
Products in Payments
- JARDIANCE (Drug) $87,138
- VERQUVO (Drug) $74,471
- Ranexa (Drug) $46,637
- ENTRESTO (Drug) $32,691
- FARXIGA (Drug) $31,051
- Inpefa (Drug) $23,718
- XARELTO (Drug) $1,330
- BRILINTA (Drug) $1,199
- Xience V coronary stent system (Device) $1,010
- Repatha (Biological) $833.54
- Vascepa (Drug) $602.79
- ELIQUIS (Drug) $565.94
- Aggrastat (tirofiban HCl) (Drug) $500.00
- Ozempic (Drug) $439.56
- CAMZYOS (Drug) $419.03
- Corlanor (Drug) $418.49
- NEXLIZET (Drug) $364.13
- LEQVIO (Drug) $362.23
- Kerendia (Drug) $352.93
- Wegovy (Drug) $337.37
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Rockville
Dr. Alexander Asser, M.d, M.D
Cardiovascular Disease — Payments: $50,047
Cardiovascular Disease $50,047
Mark Turco, M.d, M.D
Cardiovascular Disease — Payments: $28,326
Cardiovascular Disease $28,326
Dr. Mohsin Ijaz, M.d, M.D
Cardiovascular Disease — Payments: $12,942
Cardiovascular Disease $12,942
Richard Weinstein, M.d, M.D
Cardiovascular Disease — Payments: $9,368
Cardiovascular Disease $9,368
Dr. Tushina Jain, Md, MD
Cardiovascular Disease — Payments: $9,272
Cardiovascular Disease $9,272
Dennis Friedman, M.d, M.D
Cardiovascular Disease — Payments: $8,485
Cardiovascular Disease $8,485